The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the interleukin-6 gene using adenovirus vector

Cancer Research

Volumn 57, Issue 7, 1997, Pages 1335-1343

  Tanaka, Fumiaki ^a   Abe, Masako ^a   Akiyoshi, Tsuyoshi ^a   Nomura, Tatsuji ^b   Sugimachi, Keizo ^c   Kishimoto, Tadamitsu ^d   Suzuki, Tomokazu ^a   Okada, Masaji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCID MOUSE;

ADENOVIRIDAE; ADULT; AGED; ANIMALS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTERLEUKIN-6; LYMPHOCYTES; MALE; MICE; MICE, SCID; MIDDLE AGED; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030940081     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Kitahara, M., Kishimoto, S., Hirano, T., Kishimoto, T., and Okada, M. The in vivo anti-tumor effect of human recombinant interleukin-6. Jpn. J. Cancer Res., 81: 1032-1038, 1990.
2. Dranoff, G., and Mulligan, R. C. Gene transfer as cancer therapy. Adv. Immunol., 58: 417-454, 1995.
3. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995.
4. Okada, M., Klimpel, G. K., Kuppers, R. C., and Henny, C. S. The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is Lyt1 cell-dependent. J. Immunol., 122: 2527-2533, 1979.
5. Okada, M., Yoshimura, N., Kaieda, T., Yamamura, Y., and Kishimoto, T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc. Natl. Acad. Sci. USA, 78: 7717-7721, 1981.
6. Okada, M., Yoshimura, N., Ichimori, Y., Kishimoto, S., Nakai, S., Nishino, N., and Kishimoto, T. Immunologic and molecular characterization of T cell derived T cell activating factor. J. Immunol., 136: 1288-1294, 1986.
7. Okada, M., Kitahara, M., Kishimoto, S., Matsuda, T., Hirano, T., and Kishimoto, T. IL-6/BSF-2 function as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol., 141: 1543-1549, 1988.
8. Kaieda, T., Okada, M., Yoshimura, N., Kishimoto, S., Yamamura, Y., and Kishimoto, T. A human helper T cell clone secreting both killer helper factor(s) and T cell-replacing factor(s). J. Immunol., 129: 46-51, 1982.
9. Okada, M., Sakaguchi, N., Yoshimura, N., Hara, H., Shimizu, K., Yoshida, N., Yoshizaki, K., Kishimoto, S., Yamamura, Y., and Kishimoto, T. B cell growth factor and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J. Exp. Med., 157: 583-590, 1983.
10. Mule, J. J., Mcintosh, J. K., Jablons, D. M., and Rosenberg, S. A. Antitumor activity of recombinant interleukin 6 in mice. J. Exp. Med., 171: 629-636, 1990.
11. Mulé, J. J., Custer, M. C., Travis, W. D., and Rosenberg, S. A. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J. Immunol., 148: 2622-2629, 1992.
12. Okada, M., and Kishimoto, T. The potential application and limitation of cytokine/growth factor manipulation in cancer therapy. In: L. Pusztai, C. E. Lewis, and E. Yap (eds.), Cell Proliferation in Cancer; Regulatory Mechanisms of Neoplastic Cell Growth, pp. 218-244. Oxford, United Kingdom: Oxford University Press, 1996.
13. Porgador, A., Tzehoval, E., Katz, A., Vadai, E., Revel, M., Feldman, M., and Eisenbach, L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res., 52: 3679-3686, 1992.
14. Mullen, C. A., Coale, M. M., Levy, A. T., Stetler-Stevenson, W. G., Liotta, L. A., Brandt, S., and Blaese, R. M. Fibrosarcoma cells transduced with IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res., 52: 6020-6024, 1992.
15. Dougherty, G. J., Thacker, J. D., Lavey, R. S., Belldegrun, A., and McBride, W. H. Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo. Cancer Immunol. Immunother., 38: 339-345, 1994.
16. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990.
17. + T cell-dependent tumor rejection. J. Exp. Med. 174: 1291-1298, 1991.
18. Asher, A. L., Mule, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M., and Rosenberg, S. A. Murine tumor cells transduced with gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol., 146: 3227-3234, 1991.
19. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Taniyama, T., and Sakata, T. Exogeneous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorgenicity by augmented anti-tumor immunity, Proc. Natl. Acad. Sci. USA, 86: 9456-9460, 1989.
20. Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., and Parmiani, G. Granulocyte colony-stimulating factor gene transfer suppresses tumorgenicity of a murine adenocarcinoma in vivo. J. Exp. Med., 173: 889-897, 1991.
21. Tepper, R. I., Puttengale, P. K., and Leder, P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57: 503-512, 1989.
22. Golumbek, P. T., Lazenby, A. J., Levitsky, H. J., Jaffee, L. M., and Karasuyama, H. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254: 713-716, 1991.
23. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
24. Saito, S., Bannerji, R., Gansbacher, B., Rosenthal, F. M., Romanenko, P., Heston, W. D. W., Fair, W. R., and Gilboa, E. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res., 54: 3516-3520, 1994.
25. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., III, McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154: 6466-6474, 1995.
26. Okada, M., Kitahara, M., Akira, S., Shimamoto, T., Kuribayashi, K., Watanabe, Y., and Kishimoto, T. The in vivo antitumor effect of IL-6 and KHF: by using tumor cells transfected with IL-6 cDNA and SCID-hu mice via the induction of cytotoxic T cells. Adv. Allergy Immunol., 1: 13-31, 1992.
27. Li, J., Yang, Y., Fujie, T., Baba, K., Ueo, H., Mori, M., and Akiyoshi, T. Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma. Clin. Cancer Res., 2: 1619-1625, 1996.
28. Mori, M., Inoue, H., Mimori, K., Shibuta, K., Baba, K., Nakashima, H., Haraguchi, M., Tsuji, K., Ueo, H., Barnard, F. G., and Akiyoshi, T. Expression of MAGE genes in human colorectal carcinoma. Ann. Surg., 224: 183-188, 1996.
29. Inoue, H., Mori, M., Li, J., Mimori, K., Honda, M., Nakashima, H., Mafune, K., Tanaka, Y., and Akiyoshi, T. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int. J. Cancer, 63: 523-526, 1995.
30. Kanegae, Y., Makimura, M., and Saito, I. Simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol., 47: 157-166, 1994.
31. Yoshida, M., Sakuma, J., Hayashi, S., Abe, K., Saito, I., Harada, S., Sakatani, M., Yamamoto, S., Matsumoto, N., Kaneda, Y., and Kishimoto, T. A histologically distinctive interstitial pneumonia induced by overexpression of interleukin 6. transforming growth factor β1, or platelet-derived growth factor B gene. Proc. Natl. Acad. Sci. USA, 92: 9570-9574, 1995.
32. Miyake, S., Makimura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. Efficient generation of recombinant adenovirus using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. USA, 93: 1320-1324, 1996.
33. Peto, R., Pike, M., Armitage, P., Breslow, N., Cox, D., Howard, S., Mantel N., McPherson, K., Peto, J., and Smith, P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
34. Walker, W., and Gallagher, G. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice. Clin. Exp. Immunol., 101: 494-501, 1995.
35. McCune, J. M., Namikawa, R., Kaneshima, H., Shultz, L. D., Lieberman, M., and Weissman, I. L. The SCID-hu mice. Murine model for the analysis of human hematolymphoid differentiation and function. Science (Washington DC), 241: 1632-1639, 1988.
36. Mosier, D. E., Gulzia, R. J., Baird, S. M., and Wilson, D. B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (Lond.), 335: 256-259, 1988.
37. Murphy, W. J., Back, T. C., Conlon, K. C., Komschlies, K. L., Ortaldo, J. R., Sayers, T. J., Wiltrout, R. H., and Longo, D. L. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J. Clin. Invest., 92: 1918-1924, 1993.
38. Hill, L. L., Perussia, B., McCune, P., and Korngold, R. Effect on human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res., 54: 763-770, 1994.
39. Schmidt-Wolf, I. G. H., Negrin, R. S., Kiem, H-P., Blume, K. G., and Weissman, I. L. Use of SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med., 174: 139-149, 1991.
40. Takahashi, H., Nakada, T., and Puisieux, I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science (Washington DC), 259: 1460-1463, 1993.
41. Murphy, W. J., Conlon, K. C., Sayers, T. J., Wiltrout, R. H., Back, T. C., Ortaldo, J. R., and Longo, D. L. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J. Immunol., 150: 3634-3642, 1993.
42. Sabzevari, H., and Reisfeld, R. A. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res., 53: 4933-4937, 1993.
43. Barry, T. S., Jones, D. M., Richter, C. B., and Haynes, B. F. Successful engraftment of human postnatal tymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens. J. Exp. Med., 173: 167-180, 1991.
44. Murphy, W. J., Durum, S. K., and Longo, D. Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice. Proc. Natl. Acad. Sci. USA, 89: 4481-4485, 1992.
45. Alegre, M-L., Peterson, L. J., Jeyarajah, D. R., Weiser, M., Bluestone, J. A., and Thistlethwaite, J. R. Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J. Immunol., 153: 2738-2749, 1994.
46. Sandhu, J., Shpitz, B., Gallinger, S., and Hozumi, N. Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J. Immunol., 152: 3806-3813, 1994.
47. + T cell repertoire in hu-PBL-SCID chimeras. J. Exp. Med., 180: 1817-1827, 1994.
48. Bock, T. A., Orlic, D., Dunbar, C. E., Broxmeyer, H. E., and Bodine, D. M. Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J. Exp. Med., 182: 2037-2043, 1995.
49. Addison, C. L., Braciak, T., Ralston, R., Muller, W. J., Gauldie, J., and Graham, F. L. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA, 92: 8522-8526, 1995,
50. Yang, Y., Trinchieri, G., and Wilson, J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med., 1: 890-893, 1995.